Iterum Therapeutics Plc Stock Operating Margin
| ITRM Stock | USD 0.71 0.02 2.90% |
Fundamental analysis of Iterum Therapeutics allows traders to better anticipate movements in Iterum Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Iterum Therapeutics PLC Company Operating Margin Analysis
Iterum Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Iterum Therapeutics PLC has an Operating Margin of 0.0%. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Iterum Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iterum Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iterum Therapeutics could also be used in its relative valuation, which is a method of valuing Iterum Therapeutics by comparing valuation metrics of similar companies.Iterum Therapeutics is currently under evaluation in operating margin category among its peers.
Iterum Fundamentals
| Return On Equity | -5.56 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 51.28 M | ||||
| Shares Outstanding | 44.66 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 5.85 % | ||||
| Number Of Shares Shorted | 1.84 M | ||||
| Price To Earning | 16.21 X | ||||
| Price To Book | 6.03 X | ||||
| Price To Sales | 1,350 X | ||||
| Gross Profit | (941 K) | ||||
| EBITDA | (18.7 M) | ||||
| Net Income | (24.77 M) | ||||
| Cash And Equivalents | 68.91 M | ||||
| Cash Per Share | 5.63 X | ||||
| Total Debt | 45.53 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 9.47 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (26.77 M) | ||||
| Short Ratio | 2.82 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 7.0 | ||||
| Beta | 2.85 | ||||
| Market Capitalization | 31.75 M | ||||
| Total Asset | 44.59 M | ||||
| Retained Earnings | (486.07 M) | ||||
| Working Capital | 7.18 M | ||||
| Current Asset | 36.86 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 44.59 M |
About Iterum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iterum Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iterum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iterum Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Iterum Therapeutics Piotroski F Score and Iterum Therapeutics Altman Z Score analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.